arrow_back Back to App

Increased Diversity in Alzheimer's Disease Research

This act aims to increase the participation of individuals from minority groups in Alzheimer's disease clinical trials. This means research will better reflect the diversity of the population, potentially leading to more effective treatments for everyone. New research centers will be established in areas with higher concentrations of minority groups, along with diagnostic and treatment clinics tailored to their needs.
Key points
More Alzheimer's research will be conducted in areas with higher concentrations of minority groups, including at historically minority-serving institutions.
New diagnostic and treatment clinics will be established to meet the special needs of minority and rural populations.
Public outreach and education efforts will be expanded to encourage minority group members to participate in clinical trials.
Research will actively seek out principal investigators and researchers from underrepresented populations.
Eligibility criteria for clinical trials will be adjusted to allow broader patient participation, including older adults and those with mild disease.
Remote health technologies like telehealth will be used to reduce barriers to participation for minority groups.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_3085
Sponsor: Rep. Blunt Rochester, Lisa [D-DE-At Large]
Process start date: 2021-05-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ENACT Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_3085.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-05-11.

What are the main provisions?

Key points include:

  • More Alzheimer's research will be conducted in areas with higher concentrations of minority groups, including at historically minority-serving institutions.
  • New diagnostic and treatment clinics will be established to meet the special needs of minority and rural populations.
  • Public outreach and education efforts will be expanded to encourage minority group members to participate in clinical trials.
  • Research will actively seek out principal investigators and researchers from underrepresented populations.
  • Eligibility criteria for clinical trials will be adjusted to allow broader patient participation, including older adults and those with mild disease.
  • Remote health technologies like telehealth will be used to reduce barriers to participation for minority groups.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Blunt Rochester, Lisa [D-DE-At Large].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health